Central administration of oxytocin reduces hyperalgesia in mice: implication for cannabinoid and opioid systems

R. Russo, G. D'Agostino, G. Mattace Raso, C. Avagliano, C. Cristiano, R. Meli, A. Calignano

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The neuropeptide oxytocin (OXT) contributes to the regulation of diverse cognitive and physiological functions including nociception. Indeed, OXT has been reported to be analgesic when administered directly into the brain, the spinal cord, or systemically. Although many authors have reported the analgesic effects of OXT, its mechanism has not been well elucidated. Recently, it has been also hypothesize that OXT, increasing intracellular concentration of calcium, could regulate the production of mediators, like endocannabinoids (eCB). It has been well documented that eCB are able to suppress pain pathways. The present study investigates the effect of OXT in paw carrageenan-induced pain. Intracerebroventricular (icv) administration of OXT, but neither intraperitoneal nor intraplantar route, induces an antihyperalgesic effect increasing paw withdrawal latency to mechanical or thermal stimuli. Our results clearly demonstrate that 3 and 6h following carrageenan challenge, central administration of OXT (30 ng/mouse) shows a significant antihyperalgesic activity. Moreover, for the first time, we demonstrate that CB1 receptor plays a key role in the antihyperalgesic effect of OXT. In fact our results show CB1 antagonist, but not the specific CB2 antagonist reduce OXT-induced antihyperalgesic effect. In addition, our data show that central OXT administration is able to reduce carrageenan-induced hyperalgesia but does not modify carrageenan-induced paw edema. Finally, using opioid antagonists we confirm an important role of opioid receptors. In conclusion, our experiments suggest that central administration of OXT reduces hyperalgesia induced by intraplantar injection of carrageenan, and this effect may work via cannabinoid and opioid systems.
Original languageEnglish
Pages (from-to)81-88
Number of pages8
JournalPeptides
Volume38
Issue number1
Early online date10 Aug 2012
DOIs
Publication statusPublished - Nov 2012

Fingerprint

Cannabinoids
Hyperalgesia
Oxytocin
Opioid Analgesics
Carrageenan
Endocannabinoids
Analgesics
Cannabinoid Receptor CB1
Pain
Nociception
Narcotic Antagonists
Opioid Receptors
Neuropeptides
Cognition
Edema
Brain
Spinal Cord
Hot Temperature
Calcium

Keywords

  • analgesics, non-narcotic
  • animals
  • carrageenan
  • cyclooxygenase 2
  • dose-response relationship, drug
  • edema
  • hyperalgesia
  • injections, intraventricular
  • male
  • mice
  • motor activity
  • naloxone
  • narcotic antagonists
  • nitric oxide synthase type I
  • nitric oxide synthase type II
  • oxytocin
  • pain
  • receptor, cannabinoid, CB1
  • receptor, cannabinoid, CB2
  • receptors, opioid
  • receptors, oxytocin
  • spinal cord

Cite this

Russo, R., D'Agostino, G., Mattace Raso, G., Avagliano, C., Cristiano, C., Meli, R., & Calignano, A. (2012). Central administration of oxytocin reduces hyperalgesia in mice: implication for cannabinoid and opioid systems. Peptides, 38(1), 81-88. https://doi.org/10.1016/j.peptides.2012.08.005

Central administration of oxytocin reduces hyperalgesia in mice : implication for cannabinoid and opioid systems. / Russo, R.; D'Agostino, G.; Mattace Raso, G.; Avagliano, C.; Cristiano, C.; Meli, R.; Calignano, A.

In: Peptides, Vol. 38, No. 1, 11.2012, p. 81-88.

Research output: Contribution to journalArticle

Russo, R, D'Agostino, G, Mattace Raso, G, Avagliano, C, Cristiano, C, Meli, R & Calignano, A 2012, 'Central administration of oxytocin reduces hyperalgesia in mice: implication for cannabinoid and opioid systems', Peptides, vol. 38, no. 1, pp. 81-88. https://doi.org/10.1016/j.peptides.2012.08.005
Russo, R. ; D'Agostino, G. ; Mattace Raso, G. ; Avagliano, C. ; Cristiano, C. ; Meli, R. ; Calignano, A. / Central administration of oxytocin reduces hyperalgesia in mice : implication for cannabinoid and opioid systems. In: Peptides. 2012 ; Vol. 38, No. 1. pp. 81-88.
@article{08c5f2187f4242a0a109821946770962,
title = "Central administration of oxytocin reduces hyperalgesia in mice: implication for cannabinoid and opioid systems",
abstract = "The neuropeptide oxytocin (OXT) contributes to the regulation of diverse cognitive and physiological functions including nociception. Indeed, OXT has been reported to be analgesic when administered directly into the brain, the spinal cord, or systemically. Although many authors have reported the analgesic effects of OXT, its mechanism has not been well elucidated. Recently, it has been also hypothesize that OXT, increasing intracellular concentration of calcium, could regulate the production of mediators, like endocannabinoids (eCB). It has been well documented that eCB are able to suppress pain pathways. The present study investigates the effect of OXT in paw carrageenan-induced pain. Intracerebroventricular (icv) administration of OXT, but neither intraperitoneal nor intraplantar route, induces an antihyperalgesic effect increasing paw withdrawal latency to mechanical or thermal stimuli. Our results clearly demonstrate that 3 and 6h following carrageenan challenge, central administration of OXT (30 ng/mouse) shows a significant antihyperalgesic activity. Moreover, for the first time, we demonstrate that CB1 receptor plays a key role in the antihyperalgesic effect of OXT. In fact our results show CB1 antagonist, but not the specific CB2 antagonist reduce OXT-induced antihyperalgesic effect. In addition, our data show that central OXT administration is able to reduce carrageenan-induced hyperalgesia but does not modify carrageenan-induced paw edema. Finally, using opioid antagonists we confirm an important role of opioid receptors. In conclusion, our experiments suggest that central administration of OXT reduces hyperalgesia induced by intraplantar injection of carrageenan, and this effect may work via cannabinoid and opioid systems.",
keywords = "analgesics, non-narcotic, animals, carrageenan, cyclooxygenase 2, dose-response relationship, drug, edema, hyperalgesia, injections, intraventricular, male, mice, motor activity, naloxone, narcotic antagonists, nitric oxide synthase type I, nitric oxide synthase type II, oxytocin, pain, receptor, cannabinoid, CB1, receptor, cannabinoid, CB2, receptors, opioid, receptors, oxytocin, spinal cord",
author = "R. Russo and G. D'Agostino and {Mattace Raso}, G. and C. Avagliano and C. Cristiano and R. Meli and A. Calignano",
note = "Copyright {\circledC} 2012 Elsevier Inc. All rights reserved.",
year = "2012",
month = "11",
doi = "10.1016/j.peptides.2012.08.005",
language = "English",
volume = "38",
pages = "81--88",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Central administration of oxytocin reduces hyperalgesia in mice

T2 - implication for cannabinoid and opioid systems

AU - Russo, R.

AU - D'Agostino, G.

AU - Mattace Raso, G.

AU - Avagliano, C.

AU - Cristiano, C.

AU - Meli, R.

AU - Calignano, A.

N1 - Copyright © 2012 Elsevier Inc. All rights reserved.

PY - 2012/11

Y1 - 2012/11

N2 - The neuropeptide oxytocin (OXT) contributes to the regulation of diverse cognitive and physiological functions including nociception. Indeed, OXT has been reported to be analgesic when administered directly into the brain, the spinal cord, or systemically. Although many authors have reported the analgesic effects of OXT, its mechanism has not been well elucidated. Recently, it has been also hypothesize that OXT, increasing intracellular concentration of calcium, could regulate the production of mediators, like endocannabinoids (eCB). It has been well documented that eCB are able to suppress pain pathways. The present study investigates the effect of OXT in paw carrageenan-induced pain. Intracerebroventricular (icv) administration of OXT, but neither intraperitoneal nor intraplantar route, induces an antihyperalgesic effect increasing paw withdrawal latency to mechanical or thermal stimuli. Our results clearly demonstrate that 3 and 6h following carrageenan challenge, central administration of OXT (30 ng/mouse) shows a significant antihyperalgesic activity. Moreover, for the first time, we demonstrate that CB1 receptor plays a key role in the antihyperalgesic effect of OXT. In fact our results show CB1 antagonist, but not the specific CB2 antagonist reduce OXT-induced antihyperalgesic effect. In addition, our data show that central OXT administration is able to reduce carrageenan-induced hyperalgesia but does not modify carrageenan-induced paw edema. Finally, using opioid antagonists we confirm an important role of opioid receptors. In conclusion, our experiments suggest that central administration of OXT reduces hyperalgesia induced by intraplantar injection of carrageenan, and this effect may work via cannabinoid and opioid systems.

AB - The neuropeptide oxytocin (OXT) contributes to the regulation of diverse cognitive and physiological functions including nociception. Indeed, OXT has been reported to be analgesic when administered directly into the brain, the spinal cord, or systemically. Although many authors have reported the analgesic effects of OXT, its mechanism has not been well elucidated. Recently, it has been also hypothesize that OXT, increasing intracellular concentration of calcium, could regulate the production of mediators, like endocannabinoids (eCB). It has been well documented that eCB are able to suppress pain pathways. The present study investigates the effect of OXT in paw carrageenan-induced pain. Intracerebroventricular (icv) administration of OXT, but neither intraperitoneal nor intraplantar route, induces an antihyperalgesic effect increasing paw withdrawal latency to mechanical or thermal stimuli. Our results clearly demonstrate that 3 and 6h following carrageenan challenge, central administration of OXT (30 ng/mouse) shows a significant antihyperalgesic activity. Moreover, for the first time, we demonstrate that CB1 receptor plays a key role in the antihyperalgesic effect of OXT. In fact our results show CB1 antagonist, but not the specific CB2 antagonist reduce OXT-induced antihyperalgesic effect. In addition, our data show that central OXT administration is able to reduce carrageenan-induced hyperalgesia but does not modify carrageenan-induced paw edema. Finally, using opioid antagonists we confirm an important role of opioid receptors. In conclusion, our experiments suggest that central administration of OXT reduces hyperalgesia induced by intraplantar injection of carrageenan, and this effect may work via cannabinoid and opioid systems.

KW - analgesics, non-narcotic

KW - animals

KW - carrageenan

KW - cyclooxygenase 2

KW - dose-response relationship, drug

KW - edema

KW - hyperalgesia

KW - injections, intraventricular

KW - male

KW - mice

KW - motor activity

KW - naloxone

KW - narcotic antagonists

KW - nitric oxide synthase type I

KW - nitric oxide synthase type II

KW - oxytocin

KW - pain

KW - receptor, cannabinoid, CB1

KW - receptor, cannabinoid, CB2

KW - receptors, opioid

KW - receptors, oxytocin

KW - spinal cord

U2 - 10.1016/j.peptides.2012.08.005

DO - 10.1016/j.peptides.2012.08.005

M3 - Article

C2 - 22917880

VL - 38

SP - 81

EP - 88

JO - Peptides

JF - Peptides

SN - 0196-9781

IS - 1

ER -